These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39212104)

  • 1. Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof-of-Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action.
    Lane S; Lynn E; Shakir S
    Pharmacoepidemiol Drug Saf; 2024 Sep; 33(9):e70003. PubMed ID: 39212104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
    Lane S; Lynn E; Shakir S
    BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
    Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
    Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
    Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
    Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
    J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the clinical evidence leading to tetrazepam withdrawal.
    Proy-Vega B; Aguirre C; de Groot P; Solís-García del Pozo J; Jordán J
    Expert Opin Drug Saf; 2014 Jun; 13(6):705-12. PubMed ID: 24845943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
    McNaughton R; Huet G; Shakir S
    BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
    Mendes D; Alves C; Batel Marques F
    Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007.
    Aagaard L; Weber CB; Hansen EH
    Drug Saf; 2010 Apr; 33(4):327-39. PubMed ID: 20297864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.
    Arnaiz JA; Carné X; Riba N; Codina C; Ribas J; Trilla A
    Eur J Clin Pharmacol; 2001 Apr; 57(1):89-91. PubMed ID: 11372600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012.
    Bouvy JC; Huinink L; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1004-14. PubMed ID: 27146035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.